A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT01564537. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM).
Study identification
- NCT ID
- NCT01564537
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 722 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2012 (Actual)
- Primary completion
- Oct 1, 2014 (Actual)
- Completion
- Feb 8, 2022 (Actual)
- Last update posted
- Mar 10, 2023
2012 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas Medical Sciences | Little Rock | Arkansas | 72205 | — |
| Pacific Cancer Medical Center Inc | Anaheim | California | 92801 | — |
| West Contra Costa Healthcare District | Berkeley | California | 94704 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| Cancer & Blood Disease Center | Lecanto | Florida | 34461 | — |
| Northwest Georgia Oncology Center | Marietta | Georgia | 30060 | — |
| John H. Stroger, Jr. Hospital of Cook County | Chicago | Illinois | 60612 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 2215 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 7601 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Blood and Cancer Clinic | Fayetteville | North Carolina | 28303 | — |
| Scranton Hematology Oncology | Scranton | Pennsylvania | 18510 | — |
| MUSC Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Fred Hutchinson Cancer Research | Seattle | Washington | 98109 | — |
| West Virginia University Hospitals and Clinic | Morgantown | West Virginia | 26506-9300 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01564537, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2023 · Synced Nov 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01564537 live on ClinicalTrials.gov.